QUOTE AND NEWS
TheStreet.com  Aug 11  Comment 
NEW YORK (TheStreet) -- Halozyme shares are up by 7.77% to $22.75 in early afternoon trading on Tuesday, following the release of the biopharmaceutical company's 2015 second quarter earnings results yesterday. The San Diego, CA-based company...
Benzinga  Jul 31  Comment 
Eisai Co., Ltd. (OTC: ESALY) and Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that they have signed a clinical collaboration agreement to evaluate Eisai'santicancer agent eribulin mesylate (brand name: Halaven, "eribulin") in...
Benzinga  Jun 8  Comment 
Halozyme Therapeutics, Inc. (NASDAQ: HALO) shares reached a new 52-week high of $20.335. Halozyme Therapeutics announced the retirement of CFO David Ramsay and named Laurie Stelzer as his successor. JD.Com Inc(ADR) (NASDAQ: JD) shares rose...
GenEng News  Jun 5  Comment 
Halozyme said today it has launched an up-to-$1.193 billion-plus collaboration with AbbVie focused on developing and commercializing products that combine AbbVie’s compounds with Halozyme’s ENHANZE™ drug delivery platform. Under their...
FierceBiotech  Jun 4  Comment 
Halozyme Therapeutics' Enhanze tech platform essentially offers to take large molecules that would normally have to be delivered intravenously and make them available under the skin in a subcutaneous jab. And now AbbVie is jumping aboard, paying...
Benzinga  Jun 4  Comment 
In a report published Thursday, JMP Securities analyst Jason N Butler maintained a Market Outperform rating on Halozyme Therapeutics, Inc. (NASDAQ: HALO), while raising the price target from $17 to $21, after the company announced a new...
newratings.com  Jun 4  Comment 
SUMMIT (dpa-AFX) - Amicus Therapeutics (FOLD) has submitted a marketing authorization application seeking approval of its investigational Fabry monotherapy Galafold in the European Union. Galafold has accelerated assessment in the EU. Amicus also...
GenEng News  Jun 3  Comment 
Halozyme said today it has launched an up-to-$1.193 billion-plus collaboration with AbbVie focused on developing and commercializing products that combine AbbVie’s compounds with Halozyme’s ENHANZE™ drug delivery platform. Under their...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki